Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has a collaboration agreement Lund University to develop stem cell-derived treatment for Parkinson's diseases; and Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone45-4444-8888
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.72 billion
Profitability
Miscellaneous
Employees43,202
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions
What is Novo Nordisk A/S's stock symbol?
Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?
Novo Nordisk A/S declared a special dividend on Thursday, August 9th. Stockholders of record on Monday, August 20th will be given a dividend of $0.4669 per share on Tuesday, August 28th. This represents a dividend yield of 1.72%. The ex-dividend date of this dividend is Friday, August 17th. View Novo Nordisk A/S's Dividend History.
How will Novo Nordisk A/S's stock buyback program work?
Novo Nordisk A/S declared that its board has initiated a stock buyback program on Friday, February 2nd 2018, which permits the company to repurchase shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.
How were Novo Nordisk A/S's earnings last quarter?
Novo Nordisk A/S (NYSE:NVO) posted its quarterly earnings results on Friday, February, 1st. The company reported $0.54 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by $0.03. The company earned $4.55 billion during the quarter, compared to the consensus estimate of $4.36 billion. Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. View Novo Nordisk A/S's Earnings History.
When is Novo Nordisk A/S's next earnings date?
What guidance has Novo Nordisk A/S issued on next quarter's earnings?
Novo Nordisk A/S updated its FY 2019 earnings guidance on Friday, February, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17.446-17.949 billion, compared to the consensus revenue estimate of $17.91 billion.
What price target have analysts set for NVO?
15 Wall Street analysts have issued 1-year price objectives for Novo Nordisk A/S's stock. Their predictions range from $48.61 to $48.61. On average, they expect Novo Nordisk A/S's share price to reach $48.61 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.
What is the consensus analysts' recommendation for Novo Nordisk A/S?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.
Has Novo Nordisk A/S been receiving favorable news coverage?
News stories about NVO stock have trended somewhat positive on Thursday, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novo Nordisk A/S earned a coverage optimism score of 1.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term.
Who are some of Novo Nordisk A/S's key competitors?
Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG).
What other stocks do shareholders of Novo Nordisk A/S own?
Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the folowing people:
- Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
- Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
- Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
- Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
- Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs
Who are Novo Nordisk A/S's major shareholders?
Novo Nordisk A/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Saratoga Research & Investment Management (0.06%), Avalon Advisors LLC (0.02%), Tirschwell & Loewy Inc. (0.02%), Scout Investments Inc. (0.01%), Oppenheimer Asset Management Inc. (0.01%) and Ferguson Wellman Capital Management Inc. (0.01%). View Institutional Ownership Trends for Novo Nordisk A/S.
Which major investors are selling Novo Nordisk A/S stock?
NVO stock was sold by a variety of institutional investors in the last quarter, including Alta Capital Management LLC, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Autus Asset Management LLC, Brinker Capital Inc., Ingalls & Snyder LLC, Arlington Partners LLC, Gradient Investments LLC and Scout Investments Inc.. View Insider Buying and Selling for Novo Nordisk A/S.
Which major investors are buying Novo Nordisk A/S stock?
NVO stock was purchased by a variety of institutional investors in the last quarter, including Ellis Investment Partners LLC, Saratoga Research & Investment Management, Aurora Investment Counsel, OmniStar Financial Group Inc., Mercer Global Advisors Inc. ADV, Oppenheimer Asset Management Inc., Mercer Global Advisors Inc. ADV and Calamos Advisors LLC. View Insider Buying and Selling for Novo Nordisk A/S.
How do I buy shares of Novo Nordisk A/S?
Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novo Nordisk A/S's stock price today?
One share of NVO stock can currently be purchased for approximately $48.37.
How big of a company is Novo Nordisk A/S?
Novo Nordisk A/S has a market capitalization of $118.19 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.
What is Novo Nordisk A/S's official website?
How can I contact Novo Nordisk A/S?
Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]
MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
